Mode
Text Size
Log in / Sign up
N/A N=45 Randomized Quadruple-blind Other

Carnosine Loading and Periodized Training in MS and HC

Multiple Sclerosis · Exercise Therapy · Dietary Supplement

Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Beta-alanine supplementation (Dietary_supplement); Exercise intervention (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Hasselt University
Primary completion
Oct 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
VO2max
40.4; 41.2; 44; 43.4
PRIMARY
Serum Lactate
4.6; 4.4; 5.0; 5.1; 8.5; 9.2
PRIMARY
Body Composition
51.4; 49.2; 55.7; 50.3; 16.8; 15.5
PRIMARY
Strength Assessment Core Musculature
257.4; 243.3; 243.5; 256; 132.7; 145.3
PRIMARY
Workload
209; 212; 248; 235

Summary

Increasing evidence favours exercise therapy as an efficient tool to counteract inactivity related secondary symptoms in MS. Furthermore, exercise therapy may affect MS-associated muscle contractile and energy supply dysfunctions. So far, low to moderate intensity exercise rehabilitation has shown to induce small but consistent improvements in several functional parameters. High intensity exercise training in MS seems to further improve this. However, although results are promising, impairments in both muscle contraction and energy supply probably attenuate therapy outcome. In keeping with the above described physiological role of skeletal muscle carnosine and because muscle carnosine content may be lower in MS, the primary aim of the present project is to investigate whether carnosine loading improves exercise therapy outcome (exercise capacity, body composition) and performance in MS. If the latter hypothesis can be confirmed, muscle carnosine loading could be a novel intervention to improve exercise capacity and muscle function in this population.

Eligibility Criteria

Inclusion criteria

Diagnosis Multiple Sclerosis. Healthy control. Aged >18y. Written informed consent.

Exclusion criteria

Contraindications to perform moderate to high intensity exercise. Participation in another study. Experienced acute MS related exacerbation 3.5

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03418376). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search